Volume 29, issue 12, November 2022

150 articles in this issue

1. Critical Analysis of the Updated Barcelona Clinic Liver Cancer (BCLC) Group Guidelines

2. Bridging the Disparity Gap in Surgical Oncology Access: Does Telehealth Hold a Key?

3. Assessment of the PARITY Sub-Analysis “Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?”

4. Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine

5. Optimizing Sarcopenia to Strengthen Patient Outcomes After Lung and Esophageal Surgery

6. Don’t Call It a Comeback—HIPEC for Gastric Cancer

7. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy by Narayan et al.

8. Overcoming Treatment Disparities for Early-Stage Hepatocellular Carcinoma in the Veteran Population: Is the MISSION Act the Solution?

9. Utilization of National Cancer Institute-Designated Cancer Centers by Medicare Beneficiaries with Cancer

10. ‘At All Costs’: Breast Cancer Patient Responses to Cost Transparency and Communication

11. Contemporary Analysis of Sentinel Lymph Node Biopsy Performance Among Patients with Clinically Localized Merkel Cell Carcinoma

12. Avoiding Axillary Management Pitfalls After Neoadjuvant Chemotherapy

13. Telehealth Utilization Among Surgical Oncology Patients at a Large Academic Cancer Center

14. ASO Author Reflections: Improving Telehealth Access and Its Implications in a Post-Pandemic Era

15. ASO Visual Abstract: Telehealth Utilization Among Surgical Oncology Patients at a Large Academic Cancer Center

16. Use of Palliative Interventions at End of Life for Advanced Gastrointestinal Cancer

17. ASO Author Reflections: Palliative Interventions in Cancer Care Within the Last Year of Life: Unnecessary or Underutilized?

18. ASO Visual Abstract: Use of Palliative Interventions at End of Life for Advanced Gastrointestinal Cancer

19. Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma

20. Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?

21. ASO Author Reflections: Timing of Neoadjuvant Chemotherapy in Patients with Sarcoma

22. ASO Visual Abstract: Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower-Extremity Sarcomas—Does Timing Impact Complication Rates?

23. Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

24. ASO Author Reflections: Retroperitoneal Sarcoma Surgery in the Elderly

25. ASO Visual Abstract: Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

26. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

27. ASO Author Reflections: Management of Locally Recurrent Retroperitoneal Sarcoma: The Balance is Tipped Towards Biology

28. Letter to Editor Referring to the Editorial by Istl et al. ‘Good Bone Structure: A Call for Stronger Design and Methodology in Disparity Studies in Orthopedic Oncology’ Discussing the Published Article: ‘Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower-Extremity High-Grade Bone Sarcoma: A National Cancer Database Study’

29. Correction to: ASO Author Reflections: Insurance-Related Disparities in High Grade Bone Sarcoma of Lower Extremity

30. Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications

31. ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word “Rare” in Rare Cancers

32. ASO Visual Abstract: Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications

33. Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma

34. ASO Author Reflections: Colorectal Cancers with Extramural Vascular Invasion Are Associated with a Low Immune Microenvironment

35. ASO Visual Abstract: Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma

36. Metabolomic Analysis Reveals that SPHK1 Promotes Oral Squamous Cell Carcinoma Progression through NF-κB Activation

37. Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study

38. ASO Author Reflections: Changes in the Gustave Roussy Immune Score is an Important Biomarker for Therapeutic Sensitivity of Nivolumab in Gastric Cancer

39. ASO Visual Abstract: Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study

40. A Translational Randomized Trial of Perioperative Arginine Immunonutrition on Natural Killer Cell Function in Colorectal Cancer Surgery Patients

41. ASO Visual Abstract: A Translational Randomized Trial of Perioperative Arginine Immunonutrition on Natural Killer Cell Function in Colorectal Cancer Surgery Patients

42. Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells

43. ASO Author Reflections: Characteristics of Immune Evasion from Natural Killer Cells in Hepatoma Cancer Stem-Like Cells

44. PLXND1/SEMA3E Promotes Epithelial–Mesenchymal Transition Partly via the PI3K/AKT-Signaling Pathway and Induces Heterogenity in Colorectal Cancer

45. ASO Visual Abstract: PLXND1/SEMA3E Promotes EMT Partly via the PI3K/AKT Signaling Pathway and Induces Heterogeneity in Colorectal Cancer

46. Fecal Microbes Associated with the Outcomes After Esophagectomy in Patients with Esophageal Cancer

47. ASO Author Reflections: Are Fecal Microbes Associated With Outcomes After Esophageal Cancer Surgery?

48. ASO Visual Abstract: Fecal Microbes Associated with the Outcomes After Esophagectomy in Patients with Esophageal Cancer

49. Predictive Ability of the Five-time Chair Stand Test for Postoperative Pneumonia after Minimally Invasive Esophagectomy for Esophageal Cancer

50. ASO Visual Abstract: Predictive Ability of the Five-Time Chair Stand Test for Postoperative Pneumonia After Minimally Invasive Esophagectomy for Esophageal Cancer

51. Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography

52. ASO Visual Abstract: Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography

53. Disparate Access to Surgery for Operable Carcinoma of the Lung in North Carolina

54. ASO Author Reflections: Identifying and Understanding Disparities in Access to Surgery: Operable Lung Cancer in North Carolina

55. ASO Visual Abstract: Disparate Access to Surgery for Operable Carcinoma of the Lung in North Carolina

56. Robotic-Assisted Esophagectomy Leads to Significant Reduction in Postoperative Acute Pain: A Retrospective Clinical Trial

57. ASO Visual Abstract: Robotic-Assisted Esophagectomy Leads to Significant Reduction in Postoperative Acute Pain—A Retrospective Clinical Trial

58. Impact of Lymph Node Dissection on Survival and Tumor Recurrence for Patients with Resected cT1-2N0 Small Cell Lung Cancer

59. ASO Visual Abstract: Impact of Lymph Node Dissection on Survival and Tumor Recurrence in Patients with Resected cT1-2N0 Small-Cell Lung Cancer

60. Thoracoscopic Anatomical Enucleation of GGO

61. Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis

62. ASO Author Reflections: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-Analysis

63. ASO Visual Abstract: Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis—A Systematic Review and Meta-Analysis

64. Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series

65. ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series

66. ASO Visual Abstract: Co-localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series

67. Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC

68. ASO Author Reflections: Predicting Prognosis in Patients with Pseudomyxoma

69. ASO Visual Abstract: Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination after Cytoreductive Surgery and HIPEC

70. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C

71. ASO Visual Abstract: Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy—The Efficiency of Mitomycin C

72. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy

73. ASO Author Reflections: Ras-p53 Cooperativity Predicts Recurrence Patterns After Resection of Colorectal Liver Metastases with Adjuvant Local and Systemic Chemotherapy

74. ASO Visual Abstract: Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy

75. Does Intraoperative Frozen Section and Revision of Margins Lead to Improved Survival in Patients Undergoing Resection of Perihilar Cholangiocarcinoma? A Systematic Review and Meta-analysis

76. ASO Visual Abstract: Does Intraoperative Frozen Section and Revision of Margins Lead to Improved Survival for Patients Undergoing Resection of Perihilar Cholangiocarcinoma? A Systematic Review and Meta-Analysis

77. Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium

78. ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium

79. ASO Visual Abstract: Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma—Results from the US Extrahepatic Biliary Malignancy Consortium

80. Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade

81. ASO Author Reflections: Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms

82. ASO Visual Abstract: Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms—A Large-Volume Multicenter Study over One Decade

83. Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis

84. ASO Author Reflections: Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis

85. ASO Visual Abstract: Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis

86. Total Laparoscopic Resection of an Extrahepatic Mucinous Biliary Cystadenoma with Liver Involvement (with Video)

87. Factors Mediating Racial/Ethnic Disparities in Delayed Treatment of Breast Cancer

88. ASO Author Reflections: Applying the Counterfactual Approach to Disparities in Breast Cancer Treatment Delays

89. ASO Visual Abstract: Mediating Factors of Racial/Ethnic Disparities in Delayed Treatment of Breast Cancer

90. Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2− Breast Cancer

91. ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2− Breast Cancer?

92. ASO Visual Abstract: Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2– Breast Cancer

93. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes

94. ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes

95. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

96. ASO Visual Abstract: A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

97. Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS

98. ASO Visual Abstract: The Presence of Non-classic LCIS is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS

99. Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation

100. ASO Author Reflections: In an Era of De-escalation, Are We Still Doing Too Much for Stage 0 Breast Cancer?

101. ASO Visual Abstract: Overuse of Axillary Surgery for Patients With Ductal Carcinoma In Situ: Opportunity for De-Escalation

102. Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?

103. ASO Visual Abstract: Does Residual Cancer Burden Predict Local Recurrence after Neoadjuvant Chemotherapy?

104. Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer

105. ASO Visual Abstract: Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer

106. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study

107. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype

108. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer—A National Cancer Database Study

109. Individualized Risk Prediction Tool for Serious Wound Complications After Mastectomy With and Without Immediate Reconstruction

110. ASO Author Reflections: Need for Individualized Risk Prediction to Facilitate Shared Decision Making in Post-mastectomy Breast Reconstruction

111. ASO Visual Abstract: Individualized Risk Prediction Tool for Serious Wound Complications after Mastectomy with and without Immediate Reconstruction

112. Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer

113. ASO Visual Abstract: Factors Influencing Non-Sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer

114. Correction to : Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?

115. Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature

116. ASO Author Reflections: Spatial Immunophenotyping of Intraductal Papillary Mucinous Neoplasm

117. ASO Visual Abstract: Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature

118. Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study

119. ASO Author Reflections: Minimally Invasive Pancreaticoduodenectomy for Pancreatic Cancer: Are We Maximizing Delivery of Multimodality Therapy?

120. ASO Visual Abstract: Surgical Approach does not Affect Return to Intended Oncologic Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma—A Propensity Score-Matched Study

121. Long-Term Outcomes for Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms

122. ASO Visual Abstract: Long-Term Outcomes of Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms

123. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer

124. Primary Tumor Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumors (NETs): A Comparison of Upfront Surgical Resection Versus a Watch and Wait Strategy in Two Specialist NET Centers

125. ASO Visual Abstract: Primary Tumour Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumours (NET)—A Comparison of Upfront Surgical Resection versus a Watch-and-Wait Strategy in Two Specialist NET Centres

126. Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles

127. ASO Visual Abstract: Prognosis of Patients with 1–4-cm Papillary Thyroid Cancer Who Underwent Lobectomy—Focus on Gross Extrathyroidal Extension Invading Only Strap Muscles

128. Prediction of Implant Size Based on Breast Volume Using Mammography with Fully Automated Measurements and Breast MRI

129. ASO Author Reflections: Prediction of Implant Size Based on Breast Volumetry Using Mammography and Breast MRI in DTI Breast Reconstruction

130. ASO Visual Abstract: Prediction of Implant Size Based on Breast Volume Using Mammography with Fully Automated Measurement and Breast MRI

131. New Robotic System with Wristed Microinstruments Allows Precise Reconstructive Microsurgery: Preclinical Study

132. Vascularized Lymph Node Transfer Improved Outcomes of Elderly Patients with Secondary Upper Extremity Lymphedema

133. ASO Visual Abstract: Vascularized Lymph Node Transfer Improved Outcomes of Elderly Secondary Upper Extremity Lymphedema

134. Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS)

135. ASO Author Reflections: Novel Treatment De-escalation Strategies for Retropharyngeal Metastatic Disease in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS)

136. ASO Visual Abstract: Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with TransOral Robotic Surgery (TORS)

137. Correction: Trimming of Facial Artery Myomucosal Flap (FAMM) using Indocyanine Green Fluorescence Video-Angiography: Operative Nuances

138. Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter Cohort

139. ASO Author Reflections: Toward the Prediction of Peritoneal Recurrence After Curative Resection for Colon Cancer

140. ASO Visual Abstract: Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter Cohort

141. Effect of Surgical Humidification on Inflammation and Peritoneal Trauma in Colorectal Cancer Surgery: A Randomized Controlled Trial

142. ASO Visual Abstract: Effect of Surgical Humidification on Inflammation and Peritoneal Trauma in Colorectal Cancer Surgery—A Randomised Controlled Trial

143. Comments on Superior Mesenteric Artery First Approach for Right Colectomy

144. Response to Letter to the Editor: “Comments to Superior Mesenteric Artery First Approach for Right Colectomy” by Jens Marius Nesgaard et al.

145. Effect of Socioeconomic Inequalities on the Surgical Treatment and Outcomes of Patients with Colon Cancer

146. Comment on “Association of Albumin-Bilirubin Grade and Myosteatosis with its Prognostic Significance for Patients with Colorectal Cancer”

147. Reply to Letter by Min Zou et al.: Comment on “Association of Albumin–Bilirubin Grade and Myosteatosis with its Prognostic Significance for Patients with Colorectal Cancer”

148. Comments on “The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-analysis”

149. Reply to Comments on “The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-analysis”

150. Correction to: Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases